The interim results of the first ten patients with the Episealer customized knee prosthesis show
good implant safety without adverse events and improved subjective outcome scores.

This information was published, 2016-05-26 16:04 CEST (GLOBE NEWSWIRE) —

This data will be presented at the 2016 ICRS congress with the title A customized femoral resurfacing metal implant for focal chondral lesions– short term results of the first ten patients by A. Stålman, N. Martinez-Carranza, D. Roberts and M. Högström.

Postoperative X-ray images show correct implant positioning that has not changed at 12 months. The joint space is preserved at 12 months. No adverse events are registered. The subjective outcome scores improved from preoperatively to 12 months after surgery and were statistically significant (p<0,05) for VAS and all KOOS subscores except KOOS symptoms.

The scientific abstract will be presented by the main author, Anders Stålman MD PhD, at the ICRS World Congress on September 27, 2016.

”One and also two-year follow-up of the first patients confirm good patient satisfaction, and that the Episealer technique has worked well without any complications. The data to be presented forms a good basis to provide the method to a wider base of patients” says Dr Anders Stålman.

“Episurf can now report a safe and effective product that can help the so called “GAP-patients”. These are patients that are too old for cell treatment and too young for joint replacements, and such patients are quite numerous in Europe as well as in the rest of the world” comments Dr Leif Ryd, Senior Medical Advisor and Board Member, Episurf Medical.

“In line with our 2016 strategic priority to produce scientifically robust clinical evidence, this outcome demonstrates the value of our patient specific approach with the pre-surgical damage marking report, intelligent implant design and bespoke guide instrumentation. This abstract combined with the recently presented scientific abstract, “Short-term clinical results of a customized metal mini-prosthesis for focal chondral lesions”, means Episurf now has positive 1 year follow-up data on 24 patients” says Rosemary Cunningham Thomas, CEO of Episurf Medical.


For more information, please contact:

Rosemary Cunningham Thomas, CEO, Episurf Medical

Tel: +46 (0) 70-7655892

Tel: +44 (0) 7803-753603


About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention.

Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.